- Home
- TILE vs JANX Comparison
TILE vs JANX Comparison
Compare TILE & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- JANX
- Stock Information
- Founded
- TILE 1973
- JANX 2017
- Country
- TILE United States
- JANX United States
- Employees
- TILE N/A
- JANX N/A
- Industry
- TILE Home Furnishings
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- JANX Health Care
- Exchange
- TILE Nasdaq
- JANX Nasdaq
- Market Cap
- TILE 1.6B
- JANX 1.8B
- IPO Year
- TILE N/A
- JANX 2021
- Fundamental
- Price
- TILE $26.90
- JANX $30.46
- Analyst Decision
- TILE Buy
- JANX Buy
- Analyst Count
- TILE 1
- JANX 11
- Target Price
- TILE $32.00
- JANX $77.40
- AVG Volume (30 Days)
- TILE 457.6K
- JANX 1.1M
- Earning Date
- TILE 10-31-2025
- JANX 11-06-2025
- Dividend Yield
- TILE 0.30%
- JANX N/A
- EPS Growth
- TILE 33.41
- JANX N/A
- EPS
- TILE 1.92
- JANX N/A
- Revenue
- TILE $1,372,471,000.00
- JANX $10,000,000.00
- Revenue This Year
- TILE $7.40
- JANX N/A
- Revenue Next Year
- TILE $4.74
- JANX $89.91
- P/E Ratio
- TILE $13.96
- JANX N/A
- Revenue Growth
- TILE 5.11
- JANX N/A
- 52 Week Low
- TILE $17.24
- JANX $21.73
- 52 Week High
- TILE $30.20
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- TILE 54.40
- JANX 61.04
- Support Level
- TILE $25.39
- JANX $28.25
- Resistance Level
- TILE $27.03
- JANX $30.23
- Average True Range (ATR)
- TILE 0.77
- JANX 2.02
- MACD
- TILE 0.12
- JANX 0.07
- Stochastic Oscillator
- TILE 91.34
- JANX 86.39
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.